ClinicalTrials.gg
CompletedNCT04335591Updated Apr 2, 2025Results posted

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)

A Phase 3 interventional study of 75 mg linzagolix tablet and 200 mg linzagolix tablet in Endometriosis, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 47 sites in 9 countries. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
356
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing linzagolix in Endometriosis — none open to participants now, 1 under way, 1 of them phase 3. linzagolix · Endometriosis.

Started
2020
with 1 other
Phase 3
5 of 10
none open now
Registered
8th of 10
by date
Lead sponsor
9 of 10
Kissei Pharmaceutical Co., Ltd.

Among the 10 studies testing linzagolix in Endometriosis, this one is one of 2 that started in 2020, is one of 5 in phase 3, and was the 8th registered.

Endometriosis

921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.

Browse Endometriosis studies →

Open to participants now

None of the 10 studies testing linzagolix in Endometriosis is open now. The open studies under Endometriosis, anywhere →

About linzagolix

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing linzagolix in Endometriosis as a file.
02

Study summary

The primary objective of this extension study is to assess the maintenance of efficacy of linzagolix administered orally once daily for up to an additional 6 months (for up to 12 months of treatment in total) in women who have already completed 6 months of linzagolix treatment at a dose of 75 mg alone or of 200 mg in combination with ABT (E2 1 mg / NETA 0.5 mg), in the management of moderate to severe endometriosis-associated pain (EAP) in women with surgically confirmed endometriosis.

Read the detailed description

This is a prospective, randomized, double-blind study. Subjects who have completed the 6-month Treatment Period in 18-OBE2109-003 - Edelweiss 3 study (herein referred to as main study) will be invited to enter the present extension study. Month 6 visit of the main study is a decision point for Subjects to either end treatment and enter a post-treatment follow up (part of the main study), or to opt for a 6-month treatment extension.

All subjects will receive once daily either linzagolix 75 mg alone (with ABT placebo) or 200 mg combined with ABT for 6 months. Subjects who received placebo during the main study will be randomized to either linzagolix 75 mg alone (with ABT placebo) or linzagolix 200 mg with ABT. Subjects who received active treatment during the main study will continue with the same treatment. Double-dummy design will be used in order to maintain the blinding of the study.

After end of treatment in the extension study (6-month treatment period: from Month 6 to Month 12), subjects will enter a post-treatment Follow-Up Period of 6 months with no investigational medicinal product (IMP) or - for subjects willing to continue treatment - a second extension study will be proposed.

03

Conditions studied

  • Endometriosis

Keywords

  • Dysmenorrhea
  • Dyspareunia
  • Dyschezia
  • Non-menstrual pelvic pain
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The subject must have:

  • completed the 6-month treatment in the main study.
  • agree to continue to use only the analgesic rescue medication permitted by the protocol during the Treatment and Follow-up Periods.
  • To continue to comply with the requirements of the study protocol for the duration of the extension study.

Exclusion criteria

Exclusion Criteria:

The subject will be excluded if she:

  • Is pregnant or breast feeding or is planning a pregnancy within the duration of the of the study (including the Follow-up Period).
  • likely to require treatment during the study with any of the restricted medications
  • has any other gynecologic condition identified during the main study on transvaginal ultrasound (TVUS), on endometrial or at the manual breast examination, which might interfere with the study efficacy and safety objectives.
  • met any of the main study discontinuation criteria
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
356 participants (actual)

Study arms

  • Experimental
    Linzagolix 75 mg

    Drug: 75 mg linzagolix tablet · Drug: Placebo tablet to match 200 mg linzagolix tablet · Drug: Placebo capsule to match Add-back capsule

  • Experimental
    Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)

    Drug: 200 mg linzagolix tablet · Drug: Placebo tablet to match 75 mg linzagolix tablet · Drug: Add-back capsule (E2 1 mg / NETA 0.5 mg)

Interventions

  • For oral administration once daily

  • For oral administration once daily

  • DrugPlacebo tablet to match 75 mg linzagolix tablet

    For oral administration once daily

  • DrugPlacebo tablet to match 200 mg linzagolix tablet

    For oral administration once daily

  • DrugAdd-back capsule (E2 1 mg / NETA 0.5 mg)

    Drug page: Estradiol

    For oral administration once daily

  • DrugPlacebo capsule to match Add-back capsule

    For oral administration once daily

06

What researchers measure

Primary outcomes

  1. Dysmenorrhea

    Proportion of subjects with reduction of DYS (Month 3 MCT) and stable or decreased use of analgesics for EAP at Month 12

    Time frame: 6-month extension study treatment period (from Month 6 to Month 12)

  2. Non-menstrual Pelvic Pain

    Proportion of subjects with reduction of NMPP (Month 3 MCT) and stable or decreased use of analgesics for EAP at Month 12

    Time frame: 6-month extension study treatment period (from Month 6 to Month 12)

07

Results

Posted Apr 30, 2024

Participant flow

Overall, 356 subjects entered the extension study and were treated. With the exception of 3 subjects who met a discontinuation criterion at Month 6, all other subjects who entered the extension study were included in the TEAS. The PP EAS consisted of 336 subjects. All 356 subjects who entered the extension study were included in the ESAF.

Participant flow — Overall Study
MilestoneLGX 75 mgLGX 200 mg+ABTPlacebo / LGX 75 mgPlacebo / LGX 200 mg+ABT
Started1191225857
Completed1011104950
Not completed181297
Withdrew: Adverse event5232
Withdrew: Protocol violation1000
Withdrew: Withdrawal by subject8445
Withdrew: Subject planning pregnancy0100
Withdrew: Ukrainian russian war conflict4520

Outcome measures

PrimaryDysmenorrhea

Proportion of subjects with reduction of DYS (Month 3 MCT) and stable or decreased use of analgesics for EAP at Month 12

Time frame:
6-month extension study treatment period (from Month 6 to Month 12)
Reported as:
Count of participants · Participants
Dysmenorrhea
ParticipantsLGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABT
Dysmenorrhea621013243
PrimaryNon-menstrual Pelvic Pain

Proportion of subjects with reduction of NMPP (Month 3 MCT) and stable or decreased use of analgesics for EAP at Month 12

Time frame:
6-month extension study treatment period (from Month 6 to Month 12)
Reported as:
Count of participants · Participants
Non-menstrual Pelvic Pain
ParticipantsLGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABT
Non-menstrual Pelvic Pain66753427

Adverse events

Collected over 6-month extension study treatment period (from Month 6 to Month 12). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LGX 75 mg0/119 (0%)3/119 (2.5%)26/119 (21.8%)
LGX 200 mg+ABT0/122 (0%)0/122 (0%)19/122 (15.6%)
Placebo/LGX 75 mg0/58 (0%)0/58 (0%)15/58 (25.9%)
Placebo/LGX 200 mg+ABT0/57 (0%)1/57 (1.8%)13/57 (22.8%)
Most frequent serious events
Most frequent serious events
EventLGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABT
Genital haemorrhageReproductive system and breast disorders0/1190/1220/581/57
Vaginal haemorrhageReproductive system and breast disorders1/1190/1220/580/57
CholelithiasisHepatobiliary disorders1/1190/1220/580/57
AnxietyPsychiatric disorders1/1190/1220/580/57
Most frequent other events
Most frequent other events
EventLGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABT
Hot flushVascular disorders4/1195/1224/580/57
AnaemiaBlood and lymphatic system disorders7/1190/1223/582/57
HeadacheNervous system disorders5/1193/1223/583/57
Vaginal haemorrhageReproductive system and breast disorders3/1193/1221/583/57
Vulvovaginal mycotic infectionInfections and infestations1/1192/1223/583/57
COVID-19Infections and infestations6/1196/1221/582/57

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)LGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABTTotal
<=18 years00000
Between 18 and 65 years1191225857356
>=65 years00000
Age, Continuous
Age, Continuous(Years)LGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABTTotal
Mean35.1 ± 6.334.8 ± 6.934.3 ± 6.635.0 ± 7.734.8 ± 6.8
Age, Customized
Age, Customized(Years)LGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABTTotal
Median35.0 (31.0 to 40.0)35.0 (29.0 to 40.0)34.5 (30.0 to 40.0)36.0 (30.0 to 41.0)35.0 (30.0 to 40.0)
Sex: Female, Male
Sex: Female, Male(Participants)LGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABTTotal
Female1191225857356
Male00000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABTTotal
Hispanic or Latino25108
Not Hispanic or Latino1171175757348
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABTTotal
American Indian or Alaska Native00000
Asian10001
Native Hawaiian or Other Pacific Islander00000
Black or African American11013
White1171205856351
More than one race01001
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)LGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABTTotal
Austria00101
Romania674320
Czechia13004
Ukraine59503024163
Poland46512127145
Bulgaria23016
Spain10001
United States482216
Weight
Weight(kg)LGX 75 mgLGX 200 mg+ABTPlacebo/LGX 75 mgPlacebo/LGX 200 mg+ABTTotal
Mean68.475 ± 15.11565.210 ± 13.49764.004 ± 11.10368.029 ± 13.82666.560 ± 13.830

1 further baseline measures are reported on the registry.

08

Study locations

47 sites
  • Choice Research, LLC/ ID # 609
    Dothan, Alabama 36303, United States
  • Universal Axon - Homestead, LLC/ ID # 620
    Homestead, Florida 33030, United States
  • Stedman Clinical Trials/ ID # 612
    Tampa, Florida 33613, United States
  • Advanced Specialty Research/ ID # 610
    Nampa, Idaho 83687, United States
  • Women's & Family Care, LLC dba GTC Research/ ID # 608
    Shawnee Mission, Kansas 66218, United States
  • Southern Clinical Research / ID # 611
    Metairie, Louisiana 70001, United States
  • Chattanooga Medical Research LLC/ ID# 602
    Chattanooga, Tennessee 37404, United States
  • Tanner Clinic/ ID # 624
    Layton, Utah 84041, United States
  • Salzburger Landeskliniken / ID # 105
    Salzburg, 5020, Austria
  • Multiprofile Hospital for Active Treatment Sliven/ ID # 131
    Sliven, 8800, Bulgaria
  • MHAT Dr. Bratan Shukerov / ID #138
    Smolyan, Bulgaria
  • Medical Centre Excelsior /ID # 135
    Sofia, 1407, Bulgaria
  • Group Practice for Specialized Medical Assistance in GINART/ ID # 132
    Sofia, 1606, Bulgaria
  • University Multiprofile Hospital for Active Treatment "Sofiamed"/ ID # 133
    Sofia, 1797, Bulgaria
  • Gynekologicko - Porodnicka Ambulance/ ID # 162
    Tábor, 39003, Czechia
  • Gynekologie MU Dr.Lubomir Mikulasek / ID # 160
    Ujezd nad Lesy, 19016, Czechia
  • Clinique Pasteur / ID # 206
    Toulouse, 31076, France
  • Lubelskie Centrum Diagnostyczne/ ID # 402
    Świdnik, Lubelskie 21-040, Poland
  • Prywatna Klinika Ginekologiczno - Położnicza/ ID # 404
    Białystok, Podlaskie 15-224, Poland
  • Indywidualna Specjalistyczna Praktyka Lekarska Krzysztof Wilk/ ID # 411
    Katowice, 40-301, Poland
  • Clinical Medical Research sp. Z o. O/ ID # 406
    Katowice, 40-628, Poland
  • Niepubliczny Zaklad Opieki Zrowotnej GynCentrum/ ID # 407
    Katowice, 40-851, Poland
  • Kotarski Jan Specjalistyczny Gabinet Ginekologiczno Polozniczy/ ID # 405
    Lublin, 20-064, Poland
  • Centrum Medyczne Chodźki Lublin/ ID # 403
    Lublin, 20-093, Poland
  • VITA LONGA Sp. z o.o./ ID # 408
    Lublin, 20-093, Poland
  • Centrum Ginekologii Endokrynologii i Medycyny Rozrodu "Artemida"/ ID # 409
    Olsztyn, 10-357, Poland
  • Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu/ ID # 410
    Przemyśl, 37-700, Poland
  • Specjalistyczny Gabinet Lekarski Krzysztof Dynowski / ID # 401
    Warsaw, 02-929, Poland
  • Quantum Medical Center SRL/ ID # 353
    Bucharest, 12071, Romania
  • Spitalul Clinic "Nicolae Malaxa"/ ID # 352
    Bucharest, 22448, Romania
  • Centrul Medical EUROMED/ ID # 351
    Bucuresti, 20764, Romania
  • Sp Cl de Obstetrica si Ginecologie "Prof. Dr. Panait Sirbu"/ ID # 354
    Bucuresti, 60251, Romania
  • Gine Plus SRL Cluj- Napoca/ ID # 357
    Cluj-Napoca, 400698, Romania
  • Centrul Medical GALENUS/ ID # 355
    Târgu-Mureş, 540236, Romania
  • Hospital General Universitario Reina Sofia/ ID # 304
    Murcia, 30003, Spain
  • Hospital Regional Universitario de Málaga/ ID # 303
    Málaga, 29010, Spain
  • City clinical maternity hospital №1/ ID # 502
    Chernivtsi, 58003, Ukraine
  • Ivano-Frankivsk regional perinatal center, Family planning center/ ID # 506
    Ivano-Frankivs'k, 76018, Ukraine
  • Kyiv City Maternity Hospital #6/ ID # 504
    Kyiv, 02125, Ukraine
  • Medical center of LLC "Medical Center "Verum"/ ID # 503
    Kyiv, 03039, Ukraine
  • Institute of Pediatrics Obstetrics and Gynecology/ ID # 508
    Kyiv, 04050, Ukraine
  • Kyiv City Clinical Hospital #9/ ID # 501
    Kyiv, 04112, Ukraine
  • Kyiv City Center of Reproductive and Perinatal Medicine/ ID # 509
    Kyiv, 04210, Ukraine
  • Ternopil' Communal City Hospital#2 / ID # 511
    Ternopil, 46400, Ukraine
  • Vinnytsia City Clinical Hospital "Center of Mother and the Child "/ ID # 510
    Vinnytsia, 21019, Ukraine
  • Zaporizhzhya Regional Clinical Hospital/ ID # 505
    Zaporizhzhya, 69000, Ukraine
  • Maternity Hospital № 3/ ID # 507
    Zaporizhzhya, 69071, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Sep 2022, 30 months.

Results were first posted in Apr 2024, 1 year 7 months after primary completion.

Of 33 phase 3 interventional studies under Endometriosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 42. This study's 30 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2020
First posted
Apr 6, 2020
StartActual
Mar 5, 2020
Primary completionActual
Sep 15, 2022
CompletionActual
Dec 15, 2022
Results first posted
Apr 30, 2024
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04335591
Responsible party
Sponsor
First posted
Apr 6, 2020
Start date
Mar 5, 2020
Primary completion
Sep 15, 2022
Completion
Dec 15, 2022
Results posted
Apr 30, 2024
Last update
Apr 2, 2025

Study contacts

Lecomte
study director · ObsEva SA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linzagolix

Start the discussion